NeurAxis, Inc. (NRXS)Healthcare | Biotechnology | Carmel, United States | NYSE American
7.70 USD
-0.04
(-0.517%) ⇩
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 7.70 |
Hot Take ↕ | Oct. 10, 2026, 9:16 a.m. EDT
The investment case for NeurAxis is currently paralyzed by a severe disconnect between its operational narrative and its financial reality. On one hand, the company boasts impressive headline numbers: 80% year-over-year revenue growth and expanding payer coverage. However, these positives are completely overshadowed by a bottom line that remains deeply in the red, with negative operating cash flow and a trailing P/E that is mathematically undefined due to losses. The balance sheet shows significant leverage relative to equity, and the stock has failed to capitalize on this growth story, trading well below its 52-week high despite the reported surge in margins. The market's verdict appears to be that the current growth rate is insufficient to offset the burn rate and execution risks inherent in a biotech play. This skepticism is vividly reflected in the options chain, where traders are aggressively buying put protection while offering almost no call exposure for the near term. The statistical forecasting models also register a lack of directional clarity, reinforcing the view that the stock is stuck in a consolidation phase defined by uncertainty rather than momentum. Until the company can demonstrate a path to profitability or a massive de-risking event, the risk-reward profile remains skewed against the buyer. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.099852 |
| AutoETS | 0.102838 |
| MSTL | 0.105849 |
| AutoARIMA | 0.110958 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 3.56 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.109 |
| Excess Kurtosis | -0.58 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.148 |
| Revenue per Share | 0.488 |
| Market Cap | 96,694,792 |
| Forward P/E | -28.52 |
| Beta | 1.37 |
| Profit Margins | -144.44% |
| Website | https://neuraxis.com |
As of Oct. 10, 2026, 9:16 a.m. EDT: Speculators are heavily positioning for downside protection, with massive open interest in out-of-the-money puts expiring in October and November compared to negligible call volume. While there is some long-dated call activity targeting $10-$12.50 strikes, the immediate term sentiment is overwhelmingly bearish, suggesting a fear of further price erosion rather than a catalyst-driven rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.5544555 |
| Address1 | 11,611 North Meridian St |
| Address2 | Suite 330 |
| All Time High | 9.33 |
| All Time Low | 1.33 |
| Ask | 7.7 |
| Ask Size | 100 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 181,180 |
| Average Daily Volume3 Month | 124,550 |
| Average Volume | 124,550 |
| Average Volume10Days | 181,180 |
| Beta | 1.365 |
| Bid | 7.7 |
| Bid Size | 500 |
| Book Value | 0.54 |
| City | Carmel |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.7 |
| Current Ratio | 3.04 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 7.81 |
| Day Low | 7.4 |
| Debt To Equity | 4.148 |
| Display Name | NeurAxis |
| Dividend Yield | 0.0 |
| Ebitda | -7,609,116 |
| Ebitda Margins | -1.43133 |
| Enterprise To Ebitda | -11.717 |
| Enterprise To Revenue | 16.771 |
| Enterprise Value | 89,158,032 |
| Eps Current Year | -0.76 |
| Eps Forward | -0.27 |
| Eps Trailing Twelve Months | -0.78 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.597 |
| Fifty Day Average Change | 1.1029997 |
| Fifty Day Average Change Percent | 0.16719715 |
| Fifty Two Week Change Percent | 155.44556 |
| Fifty Two Week High | 9.33 |
| Fifty Two Week High Change | -1.6300001 |
| Fifty Two Week High Change Percent | -0.17470527 |
| Fifty Two Week Low | 2.21 |
| Fifty Two Week Low Change | 5.49 |
| Fifty Two Week Low Change Percent | 2.4841628 |
| Fifty Two Week Range | 2.21 - 9.33 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,691,587,800,000 |
| Float Shares | 8,332,579 |
| Forward Eps | -0.27 |
| Forward P E | -28.518517 |
| Free Cashflow | -3,154,924 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 24 |
| Fullday Change | -0.03999996 |
| Fullday Change Percent | -0.5167954 |
| Fullday Price | 7.7 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.85558 |
| Gross Profits | 4,548,382 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.25363 |
| Held Percent Institutions | 0.28437 |
| Implied Shares Outstanding | 12,557,765 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana. |
| Long Name | NeurAxis, Inc. |
| Market | us_market |
| Market Cap | 96,694,792 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_1789827517 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -8,453,122 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 91,797,262 |
| Number Of Analyst Opinions | 2 |
| Open | 7.66 |
| Operating Cashflow | -5,621,003 |
| Operating Margins | -1.10163 |
| Phone | 812 689 0791 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 7.7 |
| Post Market Time | 1,792,180,806 |
| Previous Close | 7.74 |
| Price Eps Current Year | -10.131578 |
| Price Hint | 2 |
| Price To Book | 14.259258 |
| Price To Sales Trailing12 Months | 18.188982 |
| Profit Margins | -1.44441 |
| Quick Ratio | 2.828 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.04 |
| Regular Market Change Percent | -0.516795 |
| Regular Market Day High | 7.81 |
| Regular Market Day Low | 7.4 |
| Regular Market Day Range | 7.4 - 7.81 |
| Regular Market Open | 7.66 |
| Regular Market Previous Close | 7.74 |
| Regular Market Price | 7.7 |
| Regular Market Time | 1,792,180,800 |
| Regular Market Volume | 228,980 |
| Return On Assets | -0.5621 |
| Return On Equity | -1.3975999 |
| Revenue Growth | 1.157 |
| Revenue Per Share | 0.488 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 12,557,765 |
| Shares Percent Shares Out | 0.0297 |
| Shares Short | 372,805 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 248,626 |
| Short Name | Neuraxis, Inc. |
| Short Percent Of Float | 0.0379 |
| Short Ratio | 2.45 |
| Source Interval | 15 |
| State | IN |
| Symbol | NRXS |
| Target High Price | 13.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 11.0 |
| Target Median Price | 11.0 |
| Total Cash | 8,322,258 |
| Total Cash Per Share | 0.663 |
| Total Debt | 279,392 |
| Total Revenue | 5,316,119 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.78 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.5067 |
| Two Hundred Day Average Change | 1.1932998 |
| Two Hundred Day Average Change Percent | 0.18339553 |
| Type Disp | Equity |
| Volume | 228,980 |
| Website | https://neuraxis.com |
| Zip | 46,032 |